Your browser doesn't support javascript.
loading
Thienopyrimidine-based agents bearing diphenylurea: Design, synthesis, and evaluation of antiproliferative and antiangiogenic activity.
Mohammadian, Esmaeil; Oghabi Bakhshaiesh, Tayebeh; Jouyban, Abolghasem; Nazeri, Elahe; Hasanvand, Zaman; Moghimi, Setareh; Motahari, Rasoul; Firoozpour, Loghman; Bijanzadeh, Hamidreza; Alizadeh Sani, Mahmood; Hosseinzadeh, Elaheh; Esmaeili, Rezvan; Foroumadi, Alireza.
Afiliação
  • Mohammadian E; Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Oghabi Bakhshaiesh T; Genetics Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
  • Jouyban A; Pharmaceutical Analysis Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Nazeri E; Faculty of Pharmacy, Near East University, Nicosia, North Cyprus, Turkey.
  • Hasanvand Z; Genetics Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
  • Moghimi S; Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Motahari R; Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
  • Firoozpour L; Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Bijanzadeh H; Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Alizadeh Sani M; Department of Environmental Sciences, Faculty of Natural Resources and Marine Sciences, Tarbiat Modares University, Tehran, Iran.
  • Hosseinzadeh E; Division of Food Safety and Hygiene, Department of Environmental Health, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Esmaeili R; Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
  • Foroumadi A; Genetics Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
Arch Pharm (Weinheim) ; 356(3): e2200349, 2023 Mar.
Article em En | MEDLINE | ID: mdl-36408898
ABSTRACT
An important role has been considered for the vascular endothelial growth factor receptor 2 (VEGFR-2) in the angiogenesis process, so that its inhibition is an important scientific way for cancer treatment. In this work, new thienopyrimidine derivatives were synthesized and evaluated. Compared with sorafenib, the majority of the target compounds had antiproliferative activity against the PC3, HepG2, MCF7, SW480, and HUVEC cell lines, especially 9h with IC50 values of 4.5-15.1 µM, confirming the noticeable cytotoxic effects on the listed cell lines (PC3, HepG2, SW480, and HUVEC). Analyses by flow cytometry on SW480 and HUVEC cells revealed that 9n, 9k, 9h, and 9q led to apoptotic cell death. The result of the chick chorioallantoic membrane assay showed that 9h effectively reduced the number of corresponding blood vessels. Finally, the inhibitory effect on VEGFR-2 phosphorylation was considered as the outcome of Western blot analysis of compound 9h.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptor 2 de Fatores de Crescimento do Endotélio Vascular / Antineoplásicos Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptor 2 de Fatores de Crescimento do Endotélio Vascular / Antineoplásicos Idioma: En Ano de publicação: 2023 Tipo de documento: Article